Alzheimer's disease (AD) is a major public health issue facing the world's aging population;however, to date, there is no rapid and cost effective means for early diagnosis that is widely accessible. It has been suggested that a blood-based screening will become the first-step in the AD diagnostic process, although no such test currently exists. In our prior work through the Texas Alzheimer's Research &Care Consortium (TARCC), we created a serum-based screening algorithm that correctly classified 94% of those with and without AD. We then followed that work-up by creating a blood-based algorithm in the TARCC that worked across both serum and plasma that, when applied to the ADNI plasma samples, correctly classified 89% of those with and without AD in the entirely independent cohort. The long-term goal of this project is the validation of the our blood-based screening instrument for AD.
The specific aims of the current project are as follows:
Specific Aim 1 : To test the reliability and validity of our previously created blood-based screening algorithm, and Specific Aim 2: To validate our blood-based algorithms against other diagnostic modalities (i.e., neuropathological findings and CSF analyses). Multiplex serum- and plasma-based biomarker assays (using electrochemiluminescence) will be conducted on 1,100 samples from the TARCC and Mayo Clinic Jacksonville biobanks. The establishment of a blood-based screening instrument for AD will significantly change the field of geriatric medicine. Such a tool would fit into the existing medical infrastructure as a frontline population-based screening device where positive findings can be followed-up with clinical, imaging or CSF assessments. This overall approach will increase accessibility to standard care far beyond what can be offered by other methodologies. This approach will also provide a more rapid and cost-efficient means for screening into AD clinical trials.

Public Health Relevance

Alzheimer's disease (AD) is a major public health issue facing the world's aging population;however, to date, there is no rapid and cost effective means for screening all those at risk for having the disease. The relevance of the current proposal is the establishment of a blood-based screener for AD that can be used and implemented as a frontline assessment device for clinical and research purposes. The establishment of a blood-based screener for AD would change the field of geriatric medicine and increase access to care globally.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Research Project (R01)
Project #
Application #
Study Section
Clinical Neuroscience and Neurodegeneration Study Section (CNN)
Program Officer
Hsiao, John
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Texas
Internal Medicine/Medicine
Schools of Osteopathic Medicine
Fort Worth
United States
Zip Code
Robinson, Michelle D; Mishra, Ina; Deodhar, Sneha et al. (2017) Water T2 as an early, global and practical biomarker for metabolic syndrome: an observational cross-sectional study. J Transl Med 15:258
Johnson, Leigh A; Edwards, Melissa; Gamboa, Adriana et al. (2017) Depression, inflammation, and memory loss among Mexican Americans: analysis of the HABLE cohort. Int Psychogeriatr 29:1693-1699
Villarreal, Alcibiades E; O'Bryant, Sid E; Edwards, Melissa et al. (2016) Serum-based protein profiles of Alzheimer's disease and mild cognitive impairment in elderly Hispanics. Neurodegener Dis Manag 6:203-13
O'Bryant, Sid E; Edwards, Melissa; Johnson, Leigh et al. (2016) A blood screening test for Alzheimer's disease. Alzheimers Dement (Amst) 3:83-90
Torrence, Nicole D; John, Samantha E; Gavett, Brandon E et al. (2016) An Empirical Comparison of Competing Factor Structures for the Repeatable Battery for the Assessment of Neuropsychological Status: A Project FRONTIER Study. Arch Clin Neuropsychol 31:88-96
O'Bryant, Sid E; Lista, Simone; Rissman, Robert A et al. (2016) Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges. Alzheimers Dement (Amst) 3:27-34
Chaudhari, K; Sumien, N; Johnson, L et al. (2016) Vitamin C Supplementation, APOE4 Genotype and Cognitive Functioning in a Rural-Dwelling Cohort. J Nutr Health Aging 20:841-844
Edwards, Melissa; Hall, James; Williams, Benjamin et al. (2016) Molecular markers of amnestic mild cognitive impairment among Mexican Americans. J Alzheimers Dis 49:221-8
Johnson, Leigh A; Gamboa, Adriana; Vintimilla, Raul et al. (2015) Comorbid Depression and Diabetes as a Risk for Mild Cognitive Impairment and Alzheimer's Disease in Elderly Mexican Americans. J Alzheimers Dis 47:129-36
O'Bryant, Sid E; Gupta, Veer; Henriksen, Kim et al. (2015) Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. Alzheimers Dement 11:549-60

Showing the most recent 10 out of 43 publications